“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
BEIJING (Reuters) – The World Health Organization supported China’s crusade to vaccinate some other people who oppose coronavirus in July, while clinical trials were still ongoing, a Chinese fitness official said Friday, some experts expressed fear of the decision.
China presented its emergency programme in July after contacting WHO last June, according to Zheng Zhongwei, an official of the National Health Commission.
Hundreds of thousands of must-have employees and other limited teams of others considered to be the main threat of infection gained the vaccine, its effectiveness and protection had not been fully established because Phase 3 clinical trials were incomplete, generating considerations among experts.
“In late June, the Chinese State Council approved a plan for the emergency use of the COVID-19 vaccine,” Zheng said at a press conference.
“Following approval on 29 June, we contacted the relevant representatives of WHO’s workplace in China and received WHO and understanding,” Zheng said.
Countries have the autonomy to take into account an emergency use permit for any fitness product in accordance with national and national laws, said WHO Deputy Director-General Dr. Mariangela Simo, at a press conference in Geneva on Friday.
WHO Chief Scientist Soumya Swaminathan said earlier this month that authorization for emergency use of the coronavirus vaccine is a “temporary solution” and that the long-term solution is the final touch of phase 3 trials.
Beijing has published all the main points of its emergency use programme.
At least 3 candidate vaccines, two developed through the state-sponsored National Biotec Group of China (CNBG) and one from Sinovac Biotech, all in Phase 3 trials abroad, are included in the emergency use program.
A fourth experimental vaccine developed through CanSino Biologics approved for use in the Chinese military in June.
China’s annual production capacity of COVID-19 vaccines is expected to be successful at 610 million doses by the end of 2020 and one billion doses by 2021, Zheng said.
In China, the value of the vaccine will be to the general public, Zheng added.
(Reporting through Gabriel Crossley and Roxanne Liu in Beijing; Editing through Ryan Woo and Simon Cameron-Moore)